[Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)]

Enferm Infecc Microbiol Clin. 2014 Feb;32(2):93-5. doi: 10.1016/j.eimc.2013.08.002. Epub 2013 Oct 18.
[Article in Spanish]

Abstract

Introduction: The purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice.

Methods: An observational retrospective study performed in 65 Spanish hospitals.

Results: Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count<350 cells/μl.

Conclusion: The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role.

Keywords: Antiretroviral treatment; Human immunodeficiency virus; Inhibidor de la proteasa potenciado con ritonavir; Inhibidor de la transcriptasa inversa no análogo de nucleósidos; Naive; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Tratamiento antirretroviral; Virus de la inmunodeficiencia humana.

Publication types

  • English Abstract
  • Multicenter Study
  • Observational Study

MeSH terms

  • Anti-HIV Agents / classification
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Drug Therapy, Combination
  • Drug Utilization
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects
  • HIV-1 / isolation & purification
  • Humans
  • Practice Guidelines as Topic
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Spain / epidemiology
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors